Extreme weight loss injections: the facts behind the results

Step 1, starting slow to go further

Neither Mounjaro nor Wegovy begins at the dose that produces headline results. Tirzepatide opens at 2.5 mg and semaglutide at 0.25 mg; these starter doses exist so your digestive system has time to adjust before the medicine reaches a therapeutic level. Most people notice some nausea and a reduced desire to eat almost immediately, but the weight change in the first four weeks is typically modest. That is by design. The titration schedule (moving up roughly every four weeks, guided by the prescriber) is the mechanism through which the medicine reaches its full effect.

If you want a clear picture of how that schedule compares between the two treatments, the overview of licensed weight-loss injections in the UK sets them side by side. The key point at this stage: patience with the process is not optional, it is the process.

A question our prescribers hear regularly is whether pushing through a dose increase faster will produce faster results. The evidence does not support it; the titration exists to reduce the severity of side effects, and skipping steps tends to produce more nausea without meaningfully accelerating loss.

Step 2, what the trials actually recorded

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity to tirzepatide or placebo over 72 weeks. At the highest dose, average weight reduction reached around 20–21%. Semaglutide's STEP 1 trial, also published in the NEJM, recorded around 15% average reduction at the 2.4 mg maintenance dose over 68 weeks. Both sets of numbers were unprecedented for a non-surgical weight-loss intervention.

Three things about those figures deserve emphasis. First, they are averages, some participants lost considerably more, some less. Second, the trial participants all followed a reduced-calorie diet and increased their physical activity alongside treatment; the injection does not replace those changes. Third, weight loss tends to plateau before the trial endpoints; the body adapts. NICE reviewed this evidence carefully and recommended tirzepatide in its appraisal TA1026 for adults meeting specified BMI and comorbidity thresholds.

None of this makes the results less real. It does mean the phrase "extreme weight loss" describes an outcome that emerges from a structured, medically supervised process rather than a single weight loss injection working in isolation.

Step 3, side effects to prepare for

The most common side effects are gastrointestinal: nausea, loose stools, constipation, reflux and fatigue, particularly in the weeks after starting or after a dose increase. For most people they settle within days to two weeks. Eating smaller meals, staying well hydrated and avoiding fatty or very rich food during the adjustment window all help. The safety profile of weight-loss injections is covered in more detail for people who want to work through this carefully before starting.

Some side effects require prompt medical attention. In January 2026, the MHRA issued a Drug Safety Update specifically highlighting acute pancreatitis as an infrequent but serious risk: severe, persistent stomach pain (especially if it reaches through to the back) needs urgent assessment, not watchful waiting. If you experience symptoms that concern you, your first call should be to a healthcare professional, not a forum. Suspected side effects can also be reported directly through the MHRA Yellow Card scheme.

It is worth keeping a pen and paper note of how you feel in the first few weeks, not to catastrophise, but because a clear account of symptoms makes prescriber conversations much more productive. The tablet taken before the kettle goes on, the injection done on Sunday morning: small routines reduce the chance of a missed dose and give you a natural prompt to notice how you feel.

Step 4, eligibility, access and the role of clinical assessment

The licensed eligibility for both treatments covers adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. BMI alone does not determine approval; the prescriber considers the full clinical picture, including other medications. The requirements for weight-loss injections sets out what a prescriber needs to assess before issuing a prescription.

NHS access exists but is phased and restricted: tirzepatide is being rolled out in cohorts through primary care from 2025, and Wegovy is available through specialist weight management services. Many people do not meet the current NHS thresholds, or do not want to wait. Private prescribing through a regulated pharmacy is the legal alternative, explained in full on our guide to accessing weight-loss injections in the UK. If you are thinking about cost as part of your decision, the treatment overview page sets out what is included in a private prescription at nume without hidden fees.

For anyone weighing up which injection might suit their circumstances, you can read about the 3 weight loss injections currently available and how they compare with other options on our weight loss treatment options page. And if you would like to talk through your situation with a clinician before committing to anything, speaking to our prescribers is straightforward, no obligation, no referral needed from your GP.